BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 2015;20:39-70. [DOI: 10.1016/j.drup.2015.05.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Benhabiles H, Jia J, Lejeune F. General Aspects Related to Nonsense Mutations. Nonsense Mutation Correction in Human Diseases. Elsevier; 2016. pp. 1-76. [DOI: 10.1016/b978-0-12-804468-1.00001-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Cecchin E, De Mattia E, Toffoli G. Nuclear receptors and drug metabolism for the personalization of cancer therapy. Expert Opinion on Drug Metabolism & Toxicology 2016;12:291-306. [DOI: 10.1517/17425255.2016.1141196] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
3 Caetano-pinto P, Jansen J, Assaraf YG, Masereeuw R. The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resistance Updates 2017;30:15-27. [DOI: 10.1016/j.drup.2017.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
4 De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol 2020;11:897. [PMID: 32625092 DOI: 10.3389/fphar.2020.00897] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L, Wang L, Pan H, Cao J, Zhang D, Fan S, Hua Y, Su W. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol 2017;10:22. [PMID: 28103904 DOI: 10.1186/s13045-016-0384-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
6 Wang G, Wang Y, Yang X, Zhang Y, Lu Y, Li Y. The expression and diagnostic value of serum levels of EphA2 and VEGF-A in patients with colorectal cancer. Cancer Biomark 2021;31:399-408. [PMID: 34092605 DOI: 10.3233/CBM-201745] [Reference Citation Analysis]
7 Skarkova V, Kralova V, Vitovcova B, Rudolf E. Selected Aspects of Chemoresistance Mechanisms in Colorectal Carcinoma-A Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis. Cells 2019;8:E234. [PMID: 30871055 DOI: 10.3390/cells8030234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
8 Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E467. [PMID: 30477242 DOI: 10.3390/cancers10120467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shahnam A, Ridha Z, Wiese MD, Kichenadasse G, Sorich MJ. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics 2016;17:1725-32. [DOI: 10.2217/pgs-2016-0102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Passero FC Jr, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther 2016;16:697-703. [PMID: 27219482 DOI: 10.1080/14737140.2016.1192471] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
11 Mirone G, Shukla A, Marfe G. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Crit Rev Oncol Hematol 2016;97:85-95. [PMID: 26364891 DOI: 10.1016/j.critrevonc.2015.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
12 Liu G, Liu Y, Jiang G, Ren W. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Human Cell 2018;31:189-98. [DOI: 10.1007/s13577-017-0189-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
13 Wang WD, Wu GY, Bai KH, Shu LL, Chi PD, He SY, Huang X, Zhang QY, Li L, Wang DW, Dai YJ. A prognostic stemness biomarker CCDC80 reveals acquired drug resistance and immune infiltration in colorectal cancer. Clin Transl Med 2020;10:e225. [PMID: 33135356 DOI: 10.1002/ctm2.225] [Reference Citation Analysis]
14 Jiraskova K, Hughes DJ, Brezina S, Gumpenberger T, Veskrnova V, Buchler T, Schneiderova M, Levy M, Liska V, Vodenkova S, Di Gaetano C, Naccarati A, Pardini B, Vymetalkova V, Gsur A, Vodicka P. Functional Polymorphisms in DNA Repair Genes Are Associated with Sporadic Colorectal Cancer Susceptibility and Clinical Outcome. Int J Mol Sci 2018;20:E97. [PMID: 30591675 DOI: 10.3390/ijms20010097] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
15 Chen X, Liu Y, Zhang Q, Liu B, Cheng Y, Zhang Y, Sun Y, Liu J, Gen H. Exosomal Long Non-coding RNA HOTTIP Increases Resistance of Colorectal Cancer Cells to Mitomycin via Impairing MiR-214-Mediated Degradation of KPNA3. Front Cell Dev Biol. 2020;8:582723. [PMID: 33585440 DOI: 10.3389/fcell.2020.582723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ren Y, Deng R, Cai R, Lu X, Luo Y, Wang Z, Zhu Y, Yin M, Ding Y, Lin J. TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer. Carcinogenesis 2020;41:1755-66. [PMID: 32338281 DOI: 10.1093/carcin/bgaa038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Wang N, Zhang B, Zhang Q, Su W, Guo X, Li J. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. Onco Targets Ther 2021;14:4439-50. [PMID: 34408440 DOI: 10.2147/OTT.S307273] [Reference Citation Analysis]
18 Yang C, Zhang Y, Lin S, Liu Y, Li W. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging (Albany NY) 2021;13:13515-34. [PMID: 33819186 DOI: 10.18632/aging.202774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Int J Mol Sci 2019;20:E5894. [PMID: 31771279 DOI: 10.3390/ijms20235894] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Dreussi E, Romanato L, Guardascione M, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G. Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. Front Oncol 2019;9:1312. [PMID: 31850208 DOI: 10.3389/fonc.2019.01312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G. Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Front Pharmacol 2018;9:367. [PMID: 29706892 DOI: 10.3389/fphar.2018.00367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
22 Kotelevets L, Chastre E, Desmaële D, Couvreur P. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. International Journal of Pharmaceutics 2016;514:24-40. [DOI: 10.1016/j.ijpharm.2016.06.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
23 Moody HL, Lind MJ, Maher SG. MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma. Mol Ther Nucleic Acids 2017;8:317-29. [PMID: 28918032 DOI: 10.1016/j.omtn.2017.07.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
24 Roh SA, Park IJ, Yoon YS, Kwon YH, Chung JH, Kim TW, Cho DH, Lim BH, Kim SK, Kim SY, Kim YS, Kim JC. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. J Cancer Res Clin Oncol 2016;142:1705-14. [PMID: 27177629 DOI: 10.1007/s00432-016-2177-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Cecchin E, De Mattia E, Ecca F, Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18-40. [PMID: 30075835 DOI: 10.1016/j.drup.2018.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Xu X, Chen X, Xu M, Liu X, Pan B, Qin J, Xu T, Zeng K, Pan Y, He B, Sun H, Sun L, Wang S. miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. Aging (Albany NY). 2019;11:7357-7385. [PMID: 31543507 DOI: 10.18632/aging.102214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
27 De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, Romanato L, Cecchin E, Toffoli G. A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. Front Pharmacol 2018;9:1101. [PMID: 30337874 DOI: 10.3389/fphar.2018.01101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jiang Y, Yan X, Liu K, Shi Y, Wang C, Hu J, Li Y, Wu Q, Xiang M, Zhao R. Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods. BMC Cancer 2020;20:1012. [PMID: 33076847 DOI: 10.1186/s12885-020-07507-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Chen H, Wang X, Bai J, He A. Expression, regulation and function of miR-495 in healthy and tumor tissues. Oncol Lett 2017;13:2021-6. [PMID: 28454357 DOI: 10.3892/ol.2017.5727] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
30 Mehdizadehtapeh L, Obakan Yerlİkaya P. Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors. Turk J Biol 2021;45:1-16. [PMID: 33597817 DOI: 10.3906/biy-2010-62] [Reference Citation Analysis]
31 Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, Lovero D, Silvestris F. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018;9:25355-82. [PMID: 29861877 DOI: 10.18632/oncotarget.25256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
32 Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci 2017;18:E1522. [PMID: 28708103 DOI: 10.3390/ijms18071522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
33 Chen Z, Jiang L. The clinical application of fruquintinib on colorectal cancer. Expert Review of Clinical Pharmacology 2019;12:713-21. [DOI: 10.1080/17512433.2019.1630272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
34 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 27.0] [Reference Citation Analysis]
35 Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, D'Andrea M, Pella N, Buonadonna A, Favaretto A, Toffoli G. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E1366. [PMID: 28653974 DOI: 10.3390/ijms18071366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
36 De Mattia E, Bignucolo A, Toffoli G, Cecchin E. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. Curr Med Chem 2020;27:4249-73. [PMID: 31298142 DOI: 10.2174/0929867326666190712151417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
37 De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Gagno S, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G. IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. Cancers (Basel) 2021;13:1705. [PMID: 33916844 DOI: 10.3390/cancers13071705] [Reference Citation Analysis]
38 Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 2016;43:723-37. [PMID: 27097837 DOI: 10.1111/1440-1681.12581] [Cited by in Crossref: 175] [Cited by in F6Publishing: 169] [Article Influence: 35.0] [Reference Citation Analysis]
39 De Mattia E, Cecchin E, Roncato R, Toffoli G. Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. Pharmacogenomics 2016;17:1547-71. [DOI: 10.2217/pgs-2016-0095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
40 Lv L, Liu HG, Dong SY, Yang F, Wang QX, Guo GL, Pan YF, Zhang XH. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumor Biology. 2016;37:8811-8824. [PMID: 26747179 DOI: 10.1007/s13277-015-4755-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
41 Lin Y, Chen Q, Liu QX, Zhou D, Lu X, Deng XF, Yang H, Zheng H, Qiu Y. High expression of DJ-1 promotes growth and invasion via the PTEN-AKT pathway and predicts a poor prognosis in colorectal cancer. Cancer Med 2018;7:809-19. [PMID: 29441725 DOI: 10.1002/cam4.1325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
42 Zhang J, Jiang W, Liu W, Wu J, Song L, Cheng J, Yao M, Yang L, Yao D. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo. Future Oncology 2016;12:515-24. [DOI: 10.2217/fon.15.248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
43 Li J, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Xu R, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Xu J, Chen D, Li W, Sun S, Yu Z, Cao P, Shen L, Chen H, Wang S, Wang H, Fan S, Guo X, Wang N, Han R, Zhang B, Qin S. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Adv Ther 2020;37:4585-98. [PMID: 32901330 DOI: 10.1007/s12325-020-01477-w] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Meng X, Xu Y, Lu Q, Sun L, An X, Zhang J, Chen J, Gao Y, Zhang Y, Ning X. Ultrasound-responsive alkaline nanorobots for the treatment of lactic acidosis-mediated doxorubicin resistance. Nanoscale 2020;12:13801-10. [DOI: 10.1039/d0nr03726e] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Wu H, Chen S, Yu J, Li Y, Zhang XY, Yang L, Zhang H, Hou Q, Jiang M, Brunicardi FC, Wang C, Wu S. Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells. Cancer Lett 2018;420:156-67. [PMID: 29410067 DOI: 10.1016/j.canlet.2018.01.059] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
46 Duran G, Cruz R, Simoes AR, Barros F, Giráldez JM, Bernárdez B, Anido U, Candamio S, López-López R, Carracedo Á, Lamas MJ. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics? J Chemother 2020;32:310-22. [PMID: 32441565 DOI: 10.1080/1120009X.2020.1764281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Dai DP, Yu LZ, Ye MF. LincRNA-p21 reverses irinotecan resistance in colon cancer cells via the PI3K/AKT signaling pathway. Shijie Huaren Xiaohua Zazhi 2019; 27(22): 1356-1364 [DOI: 10.11569/wcjd.v27.i22.1356] [Reference Citation Analysis]
48 Fanale D, Castiglia M, Bazan V, Russo A. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. In: Slaby O, Calin GA, editors. Non-coding RNAs in Colorectal Cancer. Cham: Springer International Publishing; 2016. pp. 207-28. [DOI: 10.1007/978-3-319-42059-2_11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
49 Bai H, Wang J, Phan CU, Chen Q, Hu X, Shao G, Zhou J, Lai L, Tang G. Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment. Nat Commun 2021;12:759. [PMID: 33536421 DOI: 10.1038/s41467-021-21071-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]